Skip to main content

Table 6 Multivariate logistic regression analysis of infliximab/vedolizumab use and hospital admission

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic Infliximab/vedolizumab use Hospital admission
OR (95% CI) P value OR (95% CI) P value
Age 0.98 (0.95–1.01) 0.20 1.00 (0.98–1.02) 0.93
CTLA-4 based therapy 1.92 (0.68–5.37) 0.22 1.26 (0.58–2.74) 0.55
Duration of ICPI treatment 1.00 (0.99–1.01) 0.17 1.00 (1.00–1.01) < 0.01
High-risk endoscopic features 3.93 (1.69–9.12) < 0.01 1.74 (0.79–3.87) 0.17
Active histological inflammation 2.32 (0.60–8.99) 0.22 1.39 (0.64–3.02) 0.40
  1. Abbreviation: ICPI immune checkpoint inhibitor, CTLA-4 cytotoxic T-lymphocyte antigen-4, OR odds ratio, CI confidence interval